# Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

> **NCT01972217** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 158 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Placebo
- **DRUG:** Abiraterone
- **DRUG:** Prednisone or prednisolone

## Key facts

- **NCT ID:** NCT01972217
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-01
- **Primary completion:** 2017-09-22
- **Final completion:** 2023-08-24
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2023-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01972217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01972217, "Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01972217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*